Skip to main content

Table 2 Summary of results of all recruited patients

From: A pilot study of topiramate dosages for migraine prophylaxis in an Asian population

Time

Baseline

Time 1

Time 2

Time 3

Frequency (days)

 25 mg

10.2 (5.1)

7.6 (6.4)

3.5 (2.2)

4.1 (1.9)

 50 mg

6.9 (2.6)

8.1 (4.2)

6.5 (4.8)

6.8 (5.7)

 75 mg

8.8 (4.4)

6.2 (5.9)

5.8 (6.6)

3.3 (4.4)

 100 mg

8.0 (2.5)

8.8 (8.2)

4.3 (2.4)

2.3 (1.5)

    

p = 0.001*

Duration (h)

 25 mg

8.4 (3.8)

9.2 (5.5)

10.1 (8.0)

6.9 (7.7)

 50 mg

8.8 (8.6)

6.0 (6.1)

5.3 (5.3)

5.9 (5.4)

 75 mg

5.3 (4.7)

7.7 (6.3)

10.9 (2.6)

12.3 (8.0)

 100 mg

7.9 (7.1)

6.4 (8.8)

7.3 (3.1)

8.0 (5.7)

    

p = 0.82

Severity (VAS)

 25 mg

5.1 (1.2)

5.1 (1.9)

5.6 (1.7)

4.9 (0.8)

 50 mg

6.3 (1.3)

6.0 (0.5)

5.1 (1.3)

5.8 (1.4)

 75 mg

5.0 (1.5)

4.4 (1.4)

4.0 (1.4)

4.3 (1.4)

 100 mg

5.7 (1.2)

5.8 (1.5)

4.8 (1.4)

4.8 (1.4)

    

p = 0.75

  1. Each row denotes mean and (SD)
  2. Each time point denotes headache diary data of the preceding 4-week period
  3. * Statistical significance (p < 0.05)